ArticleCureus2022
Anti-N-Methyl-D-Aspartate Receptor Encephalitis (ANMDARE) in a Patient With Hashimoto's Thyroiditis.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although encephalitis is more commonly caused by various infections, other etiologies that may rarely cause encephalitis must garner the attention of medical practitioners. In the realm of immune-mediated etiologies, anti-N-methyl-D-aspartate receptor encephalitis (ANMDARE) is the most common. It usually presents in a typical fashion with psychiatric symptoms followed by abnormal movements such as orofacial-lingual dyskinesia, tremor, dystonia, bradykinesia, ballism, or choreoathetosis occurring at or within the first month of onset, often affecting women and having a high correlation with ovarian teratomas. Our case report describes a 59-year-old Hispanic male with Hashimoto thyroiditis who presented with rapid cognitive decline. The diagnosis was confirmed with positive detection of NMDA receptor antibodies in the patient's cerebrospinal fluid following a lumbar puncture. The patient was treated with the first-line therapy of intravenous (IV) immunoglobulins and corticosteroids with temporary relief of symptoms. Due to the rare occurrence and possible atypical presentation of ANMDARE, this case illustrates the importance of maintaining a high index of clinical suspicion when diagnosing a patient with an unknown cause of cognitive dysfunction, especially when considering various differentials based on the patient's history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.